This document was developed by NIEHS/NTP staff to facilitate internal and external review of a proposed research program prior to designing and conducting toxicology studies. The purpose of the research concept document is to outline the general elements of a research program that would address the specific public health concerns that prompted the nomination of the substance or issue for study. It may also encompass substance-specific studies that address larger public health issues or topics in toxicology. Additional information about the nomination, review, and selection of substances for study by the NTP is provided at *Nominations to the NTP Testing Program* (*http://ntp.niehs.nih.gov/go/nom*). A draft version of this research concept was reviewed by the NTP Board of Scientific Counselors at a public meeting on December 6, 2007 (*http://ntp.niehs.nih.gov/go/9741*) and subsequently approved by the NTP Executive Committee.

NTP Research Concept: Aminopyridines

Project Leader

June K. Dunnick, Ph.D. DIR/NTP/Toxicology Branch

Nomination Background and Rationale

The National Cancer Institute (NCI) nominated aminopyridines (APs) for study because of the lack of information suitable to predict chronic toxicity for this class chemicals, and an interest in conducting structure/activity studies (http://ntp.niehs.nih.gov/go/29287). There are three APs under consideration for this nomination:

<u>2-Aminopyridine</u> (2-AP, 504-29-0) is used as an intermediate in the manufacturing of pharmaceuticals, and has a reported U. S. production of 10,000-500,000 pounds per year from 1986-2002 (except in 1998 when production climbed to 1,000,000-10,000,000 pounds). <u>3-Aminopyridine</u> (3-AP, 462-08-8) is used as an intermediate in the production of pharmaceuticals, agrochemicals and dyes. <u>4-Aminopyridine</u> (4-AP, 504-24-5), a registered pesticide, is under development as a drug to treat multiple sclerosis and other neurological diseases. Acordia Therapeutics received approval for clinical trials of Fampridine (4-AP) for treatment of multiple sclerosis (MS) in 2007 (<u>http://phx.corporate-ir.net/phoenix.zhtml?c=194451&p=irol-newsArticle&ID=1037327&highlight</u>). The proposed mechanism for 4-AP treatment of MS is prolongation of nerve action potential. No U. S. production figures are available for 3-AP or 4-AP.

There are no standard toxicity studies for the aminopyridines reported in the literature. Under the nomination, NCI requested: toxicological characterization of 2-, 3- and 4-AP including a 2-year cancer study of 2-AP; short-term mechanistic studies of 2-, 3- and 4-AP; and neurotoxicity evaluation of 2-, 3- and 4-AP. Toxicological testing of 2-AP was considered to be of relatively higher priority because of the higher production volume and potential occupational exposure.

Aminopyridines block K^+ channels in isolated nerve preparations and myocytes, and, thus, the heart and neurologic system are potential AP target organs^{3,4,11,14,16,19,21}. 4-AP is considered the most potent K^+ channel blocker followed by 3-AP and 2-AP. NTP studies of pyridine and chloropyridine identified chemical-induced liver toxicity, and, thus, liver toxicity may also occur after AP exposure due to similarities in pyridine and substituted pyridine metabolism patterns. Aminopyridines alter lymphocyte activation¹⁰ and cause apoptosis⁵, and therefore immunologic toxicity may also be a possible side effect from AP exposures.

Key Issues

- Use of toxicity tests to detect heart, liver, neurologic, or immunologic toxicity
- Relationship between rodent toxicity endpoints and blood levels of aminopyridine to levels of aminopyridines reported to block K⁺ channels

Proposed Research Program

Hypotheses

- Aminopyridines will cause neurotoxicity, cardiac toxicity and/or immunotoxicity at exposure levels that block K⁺ channels.
- Aminopyridines will cause liver toxicity at exposures levels comparable to pyridine exposures that cause liver toxicity.

Specific Aims

Toxicity studies designed to identify neurotoxicity, cardiotoxicity (including serum troponin levels or alterations in EKGs^{8,12,13}), liver toxicity, or immunotoxicity are proposed since they would help to elucidate relative toxicities of the different APs. In vitro electrophysiology studies will also be considered to analyze potential neurotoxicity. The results from these toxicity studies will be used to identify the need for chronic carcinogenicity studies or further AP mechanistic studies.

Aminopyridine metabolism/toxicokinetic studies are proposed, as they would provide information for comparing rodent AP serum levels with AP serum levels found in humans. The aminopyridines are expected to be oxidized by cytochromes P450 or flavin-containing monoxygenases yielding hydroxylated aminopyridines and aminopyridine N-oxides (see attached proposed metabolism)¹⁷.

Evaluation of changes in gene transcript levels have been used to provide a "fingerprint" of target organ toxicity (e. g. heart^{1,6,7,18} or liver^{2,9,15,20}), and such studies will be considered to understand AP toxicity pathways. Comparative genotoxicity tests and high throughput tests (HTT) (e. g. ion channel HTTs) may be used to provide additional comparative toxicity information for this class of chemicals.

Significance and Expected Outcomes

This project will provide hazard identification information for 2-, 3-, and 4aminopyridine, and provide comparative toxicity information for the aminopyridine class.




Figure 1. Plausible metabolites of 2-aminopyridine.

References

- 1 Arnett DK, Baird AE, Barkley RA, Basson CT, Boerwinkle E, Ganesh SK, Herrington DM, Hong Y, Jaquish C, McDermott DA, O'Donnell CJ: Relevance of genetics and genomics for prevention and treatment of cardiovascular disease: a scientific statement from the American Heart Association Council on Epidemiology and Prevention, the Stroke Council, and the Functional Genomics and Translational Biology Interdisciplinary Working Group. Circulation **115**: 2878-2901, 2007
- 2 Boverhof DR, Burgoon LD, Tashiro C, Sharratt B, Chittim B, Harkema JR, Mendrick DL, Zacharewski TR: Comparative toxicogenomic analysis of the hepatotoxic effects of TCDD in Sprague Dawley rats and C57BL/6 mice. Toxicol Sci **94:** 398-416, 2006
- 3 Caballero NA, Melendez FJ, Munoz-Caro C, Nino A: Theoretical prediction of relative and absolute pKa values of aminopyridines. Biophys Chem **124**: 155-160, 2006
- 4 Caballero NA, Melendez FJ, Nino A, Munoz-Caro C: Molecular docking study of the binding of aminopyridines within the K+ channel. J Mol Model **13**: 579-586, 2007
- 5 Chin LS, Park CC, Zitnay KM, Sinha M, DiPartri AJ, Jr., Perillan P, Simard JM: 4-Aminopyridine causes apoptosis and blocks an outward rectifier K⁺ channel in malignant astrocytoma cell lines. J Neurosci Res **48:** 122-127, 1997
- 6 Dunnick J, Blackshear P, Kissling G, Cunningham M, Parker J, Nyska A: Critical pathways in heart function: bis(2-chloroethoxy)methane-induced heart gene transcript change in F344 rats. Toxicol Pathol **34:** 348-356, 2006
- 7 Gaborit N, Le Bouter S, Szuts V, Varro A, Escande D, Nattel S, Demolombe S: Regional and tissue specific transcript signatures of ion channel genes in the non-diseased human heart. J Physiol **582:** 675-693, 2007
- 8 Howden R, Hanlon PR, Petranka JG, Kleeberger S, Bucher J, Dunnick J, Nyska A, Murphy E: Ephedrine plus caffeine causes age-dependent cardiovascular responses in Fischer 344 rats. Am J Physiol Heart Circ Physiol **288**: H2219-2224, 2005
- 9 Iida M, Anna CH, Hartis J, Bruno M, Wetmore B, Dubin JR, Sieber S, Bennett L, Cunningham ML, Paules RS, Tomer KB, Houle CD, Merrick AB, Sills RC, Devereux TR: Changes in global gene and protein expression during early mouse liver carcinogenesis induced by non-genotoxic model carcinogens oxazepam and Wyeth-14,643. Carcinogenesis 24: 757-770, 2003
- 10 Judge SI, Yeh JZ, Mannie MD, Pope Seifert L, Paterson PY: Potassium channel blockers inhibit adoptive transfer of experimental allergic encephaloyelitis by myelin-basicprotein-stimulated rat T lymphocytes. J Biomed Sci **4:** 169-178, 1997
- 11 Ko EA, Burg ED, Platoshyn O, Msefya J, Firth AL, Yuan JX: Functional characterization of voltage-gated K+ channels in mouse pulmonary artery smooth muscle cells. Am J Physiol Cell Physiol 293: C928-937, 2007
- 12 London B: Cardiac arrhythmias: from (transgenic) mice to men. J Cardiovasc Electrophysiol **12:** 1089-1091, 2001
- 13 London B, Guo W, Pan X, Lee JS, Shusterman V, Rocco CJ, Logothetis A, Nerbonne JM, Hill JA: Targeted replacement of Kv1.5 in the mouse leads to loss of the 4aminopyridine-sensitive component of I and resistance to drug-induced QT prolongation. Circ Res 88: 940-946 2001
- 14 Molgo J, Lemeignan M, Lechat P: Increase in evoked transmitter release from motor nerve terminals by some amino N-heterocyclic compounds. Eur J Med Chem 20: 149-153, 1985

- 15 Moto M, Okamura M, Muguruma M, Ito T, Jin M, Kashida Y, Mitsumori K: Gene expression analysis on the dicyclanil-induced hepatocellular tumors in mice. Toxicol Pathol 34: 744-751, 2006
- 16 Munoz-Caro C, Nino A: The nature of the receptor site for the reversible K+ channel blocking by aminopyridines. Biophys Chem **96:** 1-14, 2002
- 17 Namboodiri K, Osman R, Weinstein H, Rabinowitz JR: Analysis of the molecular electrostatic potential for the prediction of N-oxidation and biological activity of substituted pyridines. Molecular Toxicology **1:** 131-141, 1987
- 18 Nattel S, Maguy A, Le Bouter S, Yeh YH: Arrhythmogenic ion-channel remodeling in the heart: heart failure, myocardial infarction, and atrial fibrillation. Physiol Rev 87: 425-456, 2007
- 19 Nino A, Munoz-Caro C, Carbo-Dorca R, Girones X: Rational modelling of the voltagedependent K+ channel inactivation by aminopyridines. Biophys Chem 104: 417-427, 2003
- 20 Thomas RS, O'Connell TM, Pluta L, Wolfinger RD, Yang L, Page TJ: A comparison of transcriptomic and metabonomic technologies for identifying biomarkers predictive of two-year rodent cancer bioassays. Toxicol Sci **96:** 40-46, 2007
- 21 Wang Y, Cheng J, Tandan S, Jiang M, McCloskey DT, Hill JA: Transient-outward K+ channel inhibition facilitates L-type Ca2+ current in heart. J Cardiovasc Electrophysiol 17: 298-304, 2006

May 2008